查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2100058

遺傳性血管性水腫治療市場－2026-2032年全球市場預測

Hereditary Angioedema Therapeutics Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，遺傳性血管性水腫治療市場將成長至 73.1 億美元，複合年成長率為 5.53%。

主要市場統計數據
基準年 2025 50.1億美元
預計年份：2026年 52.8億美元
預測年份 2032 73.1億美元
複合年成長率 (%) 5.53%

遺傳性血管性水腫 (HAE) 的治療正從每次發作後的緊急治療轉向以預防為主導的個人化疾病管理，包括按需治療、短期預防和長期預防。 HAE 是一種罕見的體染色體顯性遺傳性緩激肽介導疾病，通常與 C1 酯酶阻礙要素的數量或功能缺陷有關，導致皮膚、胃腸道和呼吸道反覆腫脹。喉部病變仍然是重要的安全隱患。目前的治療策略著重於透過 C1 酯酶抑制劑替代療法、緩激肽 B2 受體拮抗劑、血漿激肽釋放酶抑制劑、因子 XIIa 抑制劑和 RNA 標靶療法，實現快速緩解、減少發作頻率、促進患者自我用藥並提高生活品質。

遺傳性血管性水腫治療格局的變革性變化

遺傳性血管性水腫的治療正受到三個相互關聯的變化的影響：早期自我給藥、更廣泛的預防性治療選擇以及激肽釋放酶-激肽通路中新的分子標靶。國際指引建議所有患者按需接受治療，並根據疾病活動度、生活品質、治療負擔、患者意願和醫療資源的可近性制定個別化的長期預防性治療方案。傳統上，血漿來源的C1-INH、lanadermab和beotralstat被用作第一線預防性治療藥物。自2025年起，監管決策新增了重要的治療方案，包括用於急性發作的口服血漿激肽釋放酶抑製劑、用於預防的XIIa因子抑製劑以及用於預防的前激肽釋放酶靶向反義寡核苷酸，這使得臨床決策不再僅僅關注給藥途徑的便利性，而是擴展到基於機制的治療順序和突發性發作的管理。

人工智慧在HAE治療中的累積影響

人工智慧正日益影響遺傳性血管性水腫 (HAE) 的治療，它並非作為單一療法，而是作為診斷、臨床試驗設計、真實世界數據和患者支持等各個環節的基礎。 HAE 常與過敏、胃腸道疾病或非特異性腫脹混淆，而利用電子健康記錄的研究表明，利用結構化和非結構化臨床數據可以主動識別可能被漏診的罕見疾病患者。在為日本開發演算法時，研究人員指出，陽性訓練資料小規模是 HAE 機器學習面臨的一項挑戰；然而，本研究表明，反覆出現的腹痛和水腫等症狀模式有助於早期診斷。激肽釋放酶-激肽路徑定量系統藥理模型也正在建立一個數據驅動的基礎，用於模擬緩激肽動力學、治療依從性、藥物動力學和預防性治療的選擇。同時，負責任的人工智慧管治對於控制偏見、可解釋性、隱私和檢驗，在種族和醫療保健系統之外仍然至關重要。

亞太地區、北美地區、拉丁美洲地區、歐洲地區以及中東和非洲地區的關鍵區域洞察

在亞太地區，遺傳性血管性水腫的治療在日本和澳洲正透過更成熟的監管途徑推進，而中國、印度、韓國和一些東南亞國家則繼續優先考慮診斷能力、專家意識和公平的醫療服務取得。一項針對亞太地區的調查顯示，許多國家仍然缺乏持續的診斷檢測和循證治療，來自印度半島的資源匱乏指南強調，在某些地區，靜脈注射的C1-INH可能是唯一可用的首選治療方案。北美仍然是一個實證醫學資源豐富、以指南主導的地區，預計美國監管機構將於2025年批准新的預防性和按需治療機制，而加拿大指南則強調綜合護理、個人化預防性治療和即時獲得癲癇治療。拉丁美洲的特點是巴西和墨西哥擁有活躍的臨床專家團隊，但在醫療服務和診斷方面仍存在差距。巴西指引建議使用艾替班特或血漿來源的C1抑制劑治療發作，但聚焦墨西哥的真實世界臨床文獻報告稱，診斷時間過長且獲得專科醫療服務的機會存在差異。歐洲受益於歐盟統一的核准、國家參考網路以及近期獲批的XIIa因子抑制劑、按需口服血漿激肽釋放酶抑制劑和RNA標靶預防藥物，但國家層級的醫保報銷體系仍是影響治療可近性的主要因素。在中東，實施全球HAE指南需要適應當地不同的認知水平、診斷可近性和自我給藥基礎設施，因此需要根據區域德爾菲法制定基於共識的建議。非洲仍然是依證最匱乏的地區，來自南非的數據顯示，按需治療的供應有限和費用問題導致疾病管理不善和生活品質下降。因此，做好緊急治療準備並建立轉診途徑是當務之急。

東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約的關鍵群體分析結果

在東協地區，遺傳性血管性水腫 (HAE) 的治療受到診斷基礎設施不均衡、C4、C1-INH 水平和 C1-INH 功能檢測的可及性差異以及專科醫生密度低等因素的阻礙，因此，區域教育、轉診流程以及可負擔的按需治療比全面的處方藥清單更為重要。在海灣合作理事會 (GCC) 地區，中東德爾菲共識強調了統一的專科醫生教育、患者自我用藥培訓以及海灣地區醫療體系對全球指南進行區域性調整的重要性。歐盟 (EU) 提供了一個健全的監管整合模式，利用集中化的藥物評估和孤兒藥核准流程，實現了最新 HAE 療法的多國核准，同時​​將報銷和患者用藥權限留給各國自行決定。在金磚國家，雖然有先進的臨床中心，但醫療資源的可近性差異很大。巴西已製定國家指南，俄羅斯正在積累最新的預防療法方面的區域經驗，印度在資源有限的情況下制定基於共識的指南，中國正在加強建立最新的專家共識並提高公眾意識，而南非由於無法獲得按需治療，其生活品質正受到顯著影響。包括美國、加拿大、英國、德國、法國、義大利和日本在內的七國集團（G7）擁有一些最成熟的遺傳性血管性水腫（HAE）醫療保健體系，這些體系中，法規核准、臨床試驗參與和專業醫療中心為實證醫學的產生和治療方案的推廣提供了支持。北約不應僅被視為藥品支付方，而應被視為持續照護和緊急應變的提供者。由於許多北約成員國與七國集團和歐盟體係有重疊，製藥公司和醫療保健網路應優先考慮跨境文件、旅行緊急應變計劃，以及與國家批准的、針對流動患者群體的按需治療方案保持一致。

主要HAE治療市場的關鍵國別洞察

在美國，由於新的遺傳性血管性水腫（HAE）治療方案獲得監管部門批准，包括因子XIIa抑制劑、按需口服激肽釋放酶抑制劑以及針對12歲及以上符合適應症患者的RNA靶向預防性治療，2025年HAE的治療選擇顯著增加。在加拿大，透過更新國際和加拿大國家指南，以及批准因子XIIa抑制劑用於12歲及以上患者的常規預防性治療，基於指南的管理正在加強。在墨西哥，未滿足的醫療需求很高，真實世界研究報告了長期診斷延遲，兒童文獻也強調了診斷不足和獲得專科治療機會不均等的問題。巴西擁有拉丁美洲最全面的HAE治療指南之一，建議使用C1-INH和緩激肽B2受體拮抗劑治療急性發作，但治療途徑的差異仍影響實際治療情況。在英國，除了近期批准的按需口服療法和RNA標靶預防療法外，還透過委託治療流程建立了一套更為系統的罕見免疫疾病臨床路徑。德國、法國、義大利和西班牙均在歐盟核准框架下運作，並受益於專業的參考中心；然而，一項針對西班牙患者臨床結局的研究仍然凸顯了在培訓、早期診斷和獲得高成本治療方面持續存在的挑戰。俄羅斯在實施最新的區域性預防療法方面取得的成就表明，這些療法在專業醫療機構中的臨床應用正在擴大，儘管各地區的可及性仍然存在差異。中國更新的專家共識以及為改善粵港澳大灣區醫療服務可近性所做的努力，標誌著人們的關注度正在從提高認知轉向系統地整合診斷和治療。印度在資源匱乏的環境下達成的共識強調了在現代治療選擇有限的情況下，應注重實用性診斷和基於C1-INH的治療。在日本，核准的遺傳性血管性水腫（HAE）治療方案正在逐步增加，官方審查文件已將icatibant、靜脈注射C1惰性療法、velotralstat、lanadermab和galadasimab列為核准藥物。在澳大利亞，隨著galadasimab於2025年獲準用於常規預防性治療以及sevetralstat獲準用於治療12歲及以上患者的癲癇發作，治療的可及性正在加速提升。在韓國，HAE的可近性與全部區域的情況類似。儘管專科醫生對疾病的認知正在提高，但各國不同的保險報銷制度和診斷標準的標準化仍然是患者能否及時啟動治療的關鍵因素。

為行業領導者提供的實用建議

產業領導者應優先考慮診斷與治療的整合，而非單一產品的定位。最可行的途徑包括：支持患者轉診至過敏科、急診科、胃腸科、小兒科、皮膚科和基層醫療等專科；確保所有確診患者均有書面行動計劃，並能獲得有效的按需治療；以及開展關於緩激肽介導的遺傳性血管性水腫 (HAE) 和組胺介導的血管性水腫之間差異的教育。鑑於接受長期預防性護理的患者仍可能經歷持續的突發性發作，且治療負擔仍取決於給藥途徑、便攜性、培訓和保險公司的批准，因此產品組合策略必須同時滿足急性期和預防性需求。領導者還應建立真實世界數據 (REW) 項目，追蹤發作頻率、開始治療的時間、急救藥物使用情況、患者報告的結局、生活品質、用藥依從性以及治療延遲的原因，並針對 C1-INH 檢測、功能性檢測、基因確診以及專科醫療中心有限的地區製定相應的准入方案。

調查方法

本執行摘要採用經驗證的實證研究方法，包括同行評審的臨床指南、系統綜述、藥物主導動態、國家治療指南、區域共識聲明以及真實世界患者和醫生調查方法。本檢驗不涉及市場規模估算、佔有率估算和預測，而是著重於臨床需求、治療機制、監管里程碑、准入障礙、診斷路徑和區域準備。資訊來源的選擇優先考慮公共監管機構、開放取用的臨床日誌、生物醫學索引資料庫和共識指南。研究結果與疾病流行病學、治療標準和監管動態進行交叉核對，以確保時效性並減少解釋偏差。國家和群體研究結果以描述性方式整合，以保持關於遺傳性血管性水腫 (HAE) 治療、C1 抑製劑缺乏症、激肽釋放酶抑製劑、緩激肽介導的血管性水腫、HAE 預防性治療、按需口服 HAE 治療以及罕見疾病說明可及性的內容一致性。

結論

遺傳性血管性水腫的治療正進入以患者為中心的新階段，其特徵是作用機制多樣化以及快速的自我給藥護理。最大的機會在於縮短診斷時間、提高檢驗的C4和C1-INH檢測的可及性、擴大專科醫生的教育範圍、確保患者能夠即時獲得按需治療，以及使預防性護理決策與患者負擔和治療目標相一致。近期在美國、歐洲、英國、澳洲、加拿大和日本的批准表明創新正在加速發展，而來自亞太地區、拉丁美洲、中東和非洲的證據表明，可操作的准入基礎設施對於治療進展至關重要。能夠將科學、實證醫學、數位科技應用和公平的護理路徑結合的領導者，最有能力改善這種罕見、不可預測且可能危及生命的疾病的治療效果。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：遺傳性血管性水腫治療市場：依治療類型分類

  • 一經請求
    • 患者主導的緊急治療
    • 臨床醫師的緊急治療
  • 長期預防性治療
  • 短期預防性治療

第8章：遺傳性血管性水腫治療市場：依藥物類別分類

  • 緩激肽受體拮抗劑
  • 血漿激肽釋放酶抑制劑
  • 雄激素
  • C1酯酶抑制劑
    • 血漿來源的C1-INH
    • 重組C1-INH

第9章：遺傳性血管性水腫療法市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 皮下

第10章：遺傳性血管性水腫治療市場：依分子模式分類

  • 重組蛋白和血漿衍生蛋白
  • 低分子化合物
  • 單株抗體（生物製劑）
  • RNA標靶治療藥物

第11章：遺傳性血管性水腫治療市場：依病患類型分類

  • 成人
  • 兒童

第12章：遺傳性血管性水腫治療市場：依最終用戶分類

  • 專科診所
  • 居家醫療
  • 醫院

第13章：遺傳性血管性水腫治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第14章：遺傳性血管性水腫治療市場：依地區分類

  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東
  • 非洲

第15章：遺傳性血管性水腫治療市場：依組別分類

  • NATO
  • G7
  • EU
  • BRICS
  • GCC
  • ASEAN

第16章：遺傳性血管性水腫治療藥物市場：依國家分類

  • 美國
  • 中國
  • 德國
  • 加拿大
  • 日本
  • 英國
  • 巴西
  • 墨西哥
  • 法國
  • 印度
  • 澳洲
  • 義大利
  • 俄羅斯
  • 韓國
  • 西班牙

第17章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • Takeda Pharmaceutical Company Limited
  • CSL Limited
  • BioCryst Pharmaceuticals, Inc.
  • Pharming Group NV
  • KalVista Pharmaceuticals, Inc.
  • Sandoz Group AG
  • Neopharmed Gentili SpA
  • Cycle Pharmaceuticals Limited
  • Teva Pharmaceutical Industries Ltd.
  • lonis Pharmaceuticals, Inc.
  • Sun Pharmaceutical Industries Limited
  • Fresenius Kabi AG
  • Alembic Pharmaceuticals Limited
  • Eugia Pharma Specialities Limited by Aurobindo Pharma Limited
  • Apotex Inc.
  • Cipla Limited
  • Glenmark Pharmaceuticals Limited
  • Adverum Biotechnologies, Inc.
  • Lupin Limited
  • ADARx Pharmaceuticals
  • AmbioPharm by Corden Pharma International GmbH
  • Argo Biopharmaceutical Co., Ltd.
  • Attune Pharmaceuticals, Inc.
  • Bachem Holding AG
  • BioMarin Pharmaceutical Inc.
  • GENESIS Pharma SA
  • Intellia Therapeutics, Inc.
  • Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
  • Kaken Pharmaceutical Co., Ltd.
  • Octapharma AG
  • Orchard Therapeutics plc
  • Otsuka Pharmaceutical Co., Ltd.
  • Pharvaris NV
  • Pint Pharma
  • Sanofi SA
  • Spark Therapeutics Inc. by F. Hoffmann-La Roche Ltd.
  • Swixx Biopharma AG
Product Code: MRR-742BD517F714

The Hereditary Angioedema Therapeutics Market is projected to grow by USD 7.31 billion at a CAGR of 5.53% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.01 billion
Estimated Year [2026] USD 5.28 billion
Forecast Year [2032] USD 7.31 billion
CAGR (%) 5.53%

Hereditary angioedema therapeutics are moving from episodic emergency intervention toward personalized, prevention-led disease control across on-demand treatment, short-term prophylaxis, and long-term prophylaxis. HAE is a rare, autosomal dominant, bradykinin-mediated disorder most often linked to quantitative or functional C1 esterase inhibitor deficiency, causing recurrent swelling of the skin, gastrointestinal tract, and airway; laryngeal involvement remains a critical safety concern. Current treatment strategies focus on rapid attack resolution, reduction of attack frequency, patient self-administration, and quality-of-life improvement through C1-INH replacement, bradykinin B2 receptor antagonism, plasma kallikrein inhibition, factor XIIa inhibition, and RNA-targeted approaches.

Transformative Shifts in the Hereditary Angioedema Treatment Landscape

The hereditary angioedema therapeutics landscape is being reshaped by three interlocking shifts: earlier self-administration, broader prophylaxis choices, and new molecular targets within the kallikrein-kinin pathway. International guidance recommends that all patients have on-demand therapy and that long-term prophylaxis be individualized based on disease activity, quality of life, treatment burden, patient preference, and health-resource availability; first-line prophylaxis has historically included plasma-derived C1-INH, lanadelumab, and berotralstat. Since 2025, regulatory decisions have added important modalities, including an oral plasma kallikrein inhibitor for acute attacks, a factor XIIa inhibitor for prevention, and a prekallikrein-directed antisense oligonucleotide for prevention, expanding clinical decision-making from route-of-administration convenience to mechanism-based sequencing and breakthrough-attack management.

Cumulative Impact of Artificial Intelligence on HAE Therapeutics

Artificial intelligence is beginning to affect hereditary angioedema therapeutics less as a stand-alone therapy and more as an enabling layer across diagnosis, trial design, real-world evidence, and patient support. HAE is frequently confused with allergy, gastrointestinal disease, or nonspecific swelling, and studies using electronic medical records show that structured and unstructured clinical data can be leveraged to proactively identify rare-disease patients who may otherwise remain undiagnosed. In Japan-focused algorithm development, researchers highlighted the difficulty of machine learning in HAE because positive training datasets are small, yet the work demonstrates how symptom patterns such as recurrent abdominal pain and edema can support earlier suspicion. Quantitative systems pharmacology models of the kallikrein-kinin pathway also create a data-driven foundation for simulating bradykinin dynamics, treatment adherence, pharmacokinetics, and prophylaxis selection, while responsible AI governance remains essential for bias control, explainability, privacy, and validation across ethnic and health-system contexts.

Key Regional Insights Across Asia-Pacific, North America, Latin America, Europe, Middle East & Africa

In Asia-Pacific, hereditary angioedema therapeutics are advancing through Japan and Australia's more established regulatory pathways while China, India, South Korea, and several Southeast Asian systems continue to prioritize diagnostic capacity, specialist awareness, and equitable access. Asia-Pacific studies report that many countries still lack consistent access to diagnostic testing and evidence-based therapies, with resource-constrained guidance from the Indian subcontinent emphasizing that intravenous plasma-derived C1-INH may be the only available first-line option in some settings. North America remains a high-evidence, guideline-driven environment, with U.S. regulatory approvals in 2025 for new prophylactic and on-demand mechanisms and Canadian guidance emphasizing comprehensive care, individualized prophylaxis, and immediate access to attack therapy. Latin America is characterized by active clinical expertise in Brazil and Mexico but persistent access and diagnosis gaps; Brazilian guidance supports crisis treatment with icatibant or plasma-derived C1 inhibitor, while Mexico-focused real-world literature documents long diagnostic delays and uneven access to specialized care. Europe benefits from centralized EU authorization, national reference networks, and recent approvals for factor XIIa inhibition, oral on-demand plasma kallikrein inhibition, and RNA-targeted prophylaxis, while country-level reimbursement remains the key determinant of treatment availability. The Middle East has developed regional Delphi consensus recommendations because implementation of global HAE guidance requires adaptation to heterogeneous awareness, diagnostic access, and self-administration infrastructure. Africa remains the most access-constrained region in the evidence base, with South African data showing that limited on-demand therapy availability and cost concerns are linked to worse disease control and quality-of-life outcomes, making emergency-treatment readiness and specialist referral pathways central priorities.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7 & NATO

Across ASEAN, hereditary angioedema therapeutics are shaped by uneven diagnostic infrastructure, variable access to C4, C1-INH level, C1-INH functional testing, and limited specialist density, making regional education, referral algorithms, and affordable on-demand treatment availability more important than broad formulary breadth. In the GCC, the Middle East Delphi consensus points to the value of harmonized specialist education, patient self-administration training, and regional adaptation of global guidance across Gulf health systems. The European Union provides a strong regulatory convergence model through centralized medicines assessment and orphan-medicine pathways, enabling multi-country authorization for recent HAE therapies while leaving reimbursement and patient access to national decision-making. BRICS countries combine advanced clinical centers with significant access heterogeneity: Brazil has national guidance, Russia has emerging regional experience with modern prophylaxis, India has resource-constrained consensus guidance, China has updated expert consensus and expanding awareness initiatives, and South Africa illustrates the quality-of-life impact of restricted on-demand access. The G7 group concentrates several of the most mature HAE care environments, including the United States, Canada, the United Kingdom, Germany, France, Italy, and Japan, where regulatory approvals, clinical trial participation, and specialist centers support evidence generation and therapy uptake. NATO should be viewed as a continuity-of-care and emergency-readiness lens rather than a medicines payer; because many NATO members overlap with G7 and EU systems, manufacturers and care networks should prioritize cross-border documentation, travel-ready rescue plans, and alignment with nationally approved on-demand options for mobile populations.

Key Country Insights Across Major HAE Therapeutics Markets

In the United States, 2025 marked a major therapeutic expansion as regulators cleared new HAE options spanning factor XIIa inhibition, oral on-demand kallikrein inhibition, and RNA-targeted prophylaxis for patients aged 12 years and older where indicated. Canada is reinforcing guideline-based management through updated international and Canadian recommendations and authorization of factor XIIa inhibition for routine prevention in patients 12 years and older. Mexico shows a high unmet-need profile, with real-world research describing long diagnostic delays and pediatric literature calling out underdiagnosis and inequitable access to specialized therapies. Brazil has one of Latin America's strongest documented HAE guidance bases, with recommendations supporting C1-INH and bradykinin B2 receptor antagonist use for acute crises while access pathways continue to shape real-world treatment. In the United Kingdom, recent approvals for oral on-demand treatment and RNA-targeted prophylaxis, alongside commissioned treatment algorithms, support a more structured rare-immunology pathway. Germany, France, Italy, and Spain operate within the EU authorization framework and benefit from specialist reference centers, but Spain-specific patient-journey research still identifies training, early diagnosis, and high-cost therapy access as continuing issues. Russia's recent regional experience with modern prophylaxis indicates growing clinical adoption in specialist settings, although availability remains location-dependent. China's updated expert consensus and Greater Bay Area access initiatives show a shift from awareness-building toward structured diagnosis and treatment alignment. India's consensus for resource-constrained settings emphasizes pragmatic diagnosis and C1-INH-based management where modern options are limited. Japan has progressively broadened approved HAE options, with official review documents listing icatibant, intravenous C1-inactivator therapy, berotralstat, lanadelumab, and garadacimab among approved medicines. Australia has accelerated access with 2025 approval of garadacimab for routine prevention and approval of sebetralstat for attacks in patients aged 12 years and older. South Korea sits within the wider Asia-Pacific access pattern, where specialist awareness is improving but country-specific reimbursement and diagnostic standardization remain decisive for patient-level uptake.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize diagnosis-to-treatment integration rather than isolated product positioning. The most actionable pathway is to support specialist referral triggers in allergy, emergency medicine, gastroenterology, pediatrics, dermatology, and primary care; ensure every diagnosed patient has a written action plan and access to effective on-demand treatment; and design education around the difference between bradykinin-mediated HAE and histamine-mediated angioedema. Portfolio strategy should address both acute and preventive needs because breakthrough attacks can persist even in patients receiving long-term prophylaxis, and treatment burden remains tied to route of administration, portability, training, and payer authorization. Leaders should also build real-world evidence programs that track attack frequency, time to treatment, rescue-medication use, patient-reported outcomes, quality of life, adherence, and reasons for delayed treatment, while tailoring access programs for regions where C1-INH testing, functional assays, genetic confirmation, and specialist centers are limited.

Research Methodology

This executive summary applies a verified, evidence-led methodology using peer-reviewed clinical guidelines, systematic reviews, regulatory drug snapshots, national treatment guidance, regional consensus statements, and real-world patient or physician surveys. The analysis excludes market sizing, share estimation, and forecasting, and instead focuses on clinical need, treatment mechanisms, regulatory milestones, access barriers, diagnostic pathways, and regional readiness. Source prioritization favored official regulators, open-access clinical journals, indexed biomedical databases, and consensus guidance; findings were cross-checked across disease epidemiology, treatment standards, and regulatory updates to maintain recency and reduce interpretation bias. Country and group insights were synthesized narratively to preserve for hereditary angioedema therapeutics, C1 inhibitor deficiency, kallikrein inhibitors, bradykinin-mediated angioedema, HAE prophylaxis, oral on-demand HAE therapy, and rare disease treatment access.

Conclusion

Hereditary angioedema therapeutics have entered a new phase defined by patient-centered control, mechanism diversity, and faster self-administered care. The strongest opportunities lie in shortening the diagnostic odyssey, improving availability of validated C4 and C1-INH testing, expanding specialist education, ensuring immediate access to on-demand therapy, and matching prophylaxis decisions to patient burden and treatment goals. Recent approvals across the United States, Europe, the United Kingdom, Australia, Canada, and Japan demonstrate accelerating innovation, while evidence from Asia-Pacific, Latin America, the Middle East, and Africa shows that therapeutic progress must be paired with practical access infrastructure. Leaders that connect science, evidence generation, digital enablement, and equitable care pathways will be best positioned to improve outcomes in this rare, unpredictable, and potentially life-threatening condition.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
      • 4.3.1.1. Prioritize Convenience as Oral and Lower-Burden Therapies Reset Patient Expectations
      • 4.3.1.2. Expand Pediatric Pathways to Build Lifetime Treatment Value and Caregiver Loyalty
      • 4.3.1.3. Use Modality Innovation to Broaden Treatment Choice and Attract Strategic Investment
      • 4.3.1.4. Leverage Specialty Pharmacy and Home-Care Infrastructure to Convert Prescriptions into Persistent Use
    • 4.3.2. Key Restraints
      • 4.3.2.1. Prove Premium Value to Overcome Payer Controls and Rare-Disease Budget Pressure
      • 4.3.2.2. Strengthen Supply Resilience to Protect Continuity in a High-Risk Specialty Market
    • 4.3.3. Key Opportunities
      • 4.3.3.1. Scale Oral Rescue Therapy as the New Standard for Patient-Initiated Attack Management
      • 4.3.3.2. Commercialize Long-Acting Prophylaxis to Reduce Treatment Burden and Improve Persistence
      • 4.3.3.3. Unlock Underdiagnosed Geographies Through AI-Enabled Screening and Regional Access Partnerships
    • 4.3.4. Key Challenges
      • 4.3.4.1. Convert Underdiagnosed Patients into Treatable Demand Through Education and Data-Driven Identification
      • 4.3.4.2. Navigate Payer Crowding as Multiple Premium HAE Options Compete for Preferred Access
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Hereditary Angioedema Therapeutics Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. On Demand
    • 7.2.1. Patient-Initiated Rescue
    • 7.2.2. Clinician-Administered Rescue
  • 7.3. Long-Term Prophylaxis
  • 7.4. Short-Term Prophylaxis

8. Hereditary Angioedema Therapeutics Market, by Drug Class

  • 8.1. Introduction
  • 8.2. Bradykinin Receptor Antagonist
  • 8.3. Plasma Kallikrein Inhibitors
  • 8.4. Androgens
  • 8.5. C1-Esterase Inhibitors
    • 8.5.1. Plasma-Derived C1-INH
    • 8.5.2. Recombinant C1-INH

9. Hereditary Angioedema Therapeutics Market, by Route Of Administration

  • 9.1. Introduction
  • 9.2. Intravenous
  • 9.3. Oral
  • 9.4. Subcutaneous

10. Hereditary Angioedema Therapeutics Market, by Molecule Modality

  • 10.1. Introduction
  • 10.2. Recombinant & Plasma-Derived Proteins
  • 10.3. Small Molecules
  • 10.4. Monoclonal Antibodies (Biologics)
  • 10.5. RNA-Targeted Therapeutic

11. Hereditary Angioedema Therapeutics Market, by Patient Type

  • 11.1. Introduction
  • 11.2. Adult
  • 11.3. Pediatric

12. Hereditary Angioedema Therapeutics Market, by End User

  • 12.1. Introduction
  • 12.2. Specialty Clinics
  • 12.3. Home Care Settings
  • 12.4. Hospital

13. Hereditary Angioedema Therapeutics Market, by Distribution Channel

  • 13.1. Introduction
  • 13.2. Hospital Pharmacies
  • 13.3. Online Pharmacies
  • 13.4. Retail Pharmacies

14. Hereditary Angioedema Therapeutics Market, by Region

  • 14.1. North America
  • 14.2. Europe
  • 14.3. Asia-Pacific
  • 14.4. Latin America
  • 14.5. Middle East
  • 14.6. Africa

15. Hereditary Angioedema Therapeutics Market, by Group

  • 15.1. NATO
  • 15.2. G7
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. GCC
  • 15.6. ASEAN

16. Hereditary Angioedema Therapeutics Market, by Country

  • 16.1. United States
  • 16.2. China
  • 16.3. Germany
  • 16.4. Canada
  • 16.5. Japan
  • 16.6. United Kingdom
  • 16.7. Brazil
  • 16.8. Mexico
  • 16.9. France
  • 16.10. India
  • 16.11. Australia
  • 16.12. Italy
  • 16.13. Russia
  • 16.14. South Korea
  • 16.15. Spain

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2025
  • 17.2. FPNV Positioning Matrix, 2025
  • 17.3. Market Concentration Analysis, 2025
    • 17.3.1. Concentration Ratio (CR)
    • 17.3.2. Herfindahl Hirschman Index (HHI)
  • 17.4. Recent Developments & Impact Analysis, 2025
  • 17.5. Product Portfolio Analysis, 2025
  • 17.6. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. Takeda Pharmaceutical Company Limited
  • 18.2. CSL Limited
  • 18.3. BioCryst Pharmaceuticals, Inc.
  • 18.4. Pharming Group N.V.
  • 18.5. KalVista Pharmaceuticals, Inc.
  • 18.6. Sandoz Group AG
  • 18.7. Neopharmed Gentili S.p.A.
  • 18.8. Cycle Pharmaceuticals Limited
  • 18.9. Teva Pharmaceutical Industries Ltd.
  • 18.10. lonis Pharmaceuticals, Inc.
  • 18.11. Sun Pharmaceutical Industries Limited
  • 18.12. Fresenius Kabi AG
  • 18.13. Alembic Pharmaceuticals Limited
  • 18.14. Eugia Pharma Specialities Limited by Aurobindo Pharma Limited
  • 18.15. Apotex Inc.
  • 18.16. Cipla Limited
  • 18.17. Glenmark Pharmaceuticals Limited
  • 18.18. Adverum Biotechnologies, Inc.
  • 18.19. Lupin Limited
  • 18.20. ADARx Pharmaceuticals
  • 18.21. AmbioPharm by Corden Pharma International GmbH
  • 18.22. Argo Biopharmaceutical Co., Ltd.
  • 18.23. Attune Pharmaceuticals, Inc.
  • 18.24. Bachem Holding AG
  • 18.25. BioMarin Pharmaceutical Inc.
  • 18.26. GENESIS Pharma S.A.
  • 18.27. Intellia Therapeutics, Inc.
  • 18.28. Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
  • 18.29. Kaken Pharmaceutical Co., Ltd.
  • 18.30. Octapharma AG
  • 18.31. Orchard Therapeutics plc
  • 18.32. Otsuka Pharmaceutical Co., Ltd.
  • 18.33. Pharvaris N.V.
  • 18.34. Pint Pharma
  • 18.35. Sanofi S.A.
  • 18.36. Spark Therapeutics Inc. by F. Hoffmann-La Roche Ltd.
  • 18.37. Swixx Biopharma AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 27. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ON DEMAND MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ON DEMAND MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ON DEMAND MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PATIENT-INITIATED RESCUE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PATIENT-INITIATED RESCUE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PATIENT-INITIATED RESCUE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CLINICIAN-ADMINISTERED RESCUE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CLINICIAN-ADMINISTERED RESCUE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CLINICIAN-ADMINISTERED RESCUE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LONG-TERM PROPHYLAXIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LONG-TERM PROPHYLAXIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LONG-TERM PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SHORT-TERM PROPHYLAXIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SHORT-TERM PROPHYLAXIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SHORT-TERM PROPHYLAXIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BRADYKININ RECEPTOR ANTAGONIST MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRADYKININ RECEPTOR ANTAGONIST MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BRADYKININ RECEPTOR ANTAGONIST MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PLASMA KALLIKREIN INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PLASMA KALLIKREIN INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PLASMA KALLIKREIN INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANDROGENS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANDROGENS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANDROGENS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL C1-ESTERASE INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL C1-ESTERASE INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL C1-ESTERASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PLASMA-DERIVED C1-INH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PLASMA-DERIVED C1-INH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PLASMA-DERIVED C1-INH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL RECOMBINANT C1-INH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RECOMBINANT C1-INH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RECOMBINANT C1-INH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RECOMBINANT & PLASMA-DERIVED PROTEINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RECOMBINANT & PLASMA-DERIVED PROTEINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RECOMBINANT & PLASMA-DERIVED PROTEINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SMALL MOLECULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SMALL MOLECULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SMALL MOLECULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MONOCLONAL ANTIBODIES (BIOLOGICS) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MONOCLONAL ANTIBODIES (BIOLOGICS) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MONOCLONAL ANTIBODIES (BIOLOGICS) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL RNA-TARGETED THERAPEUTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL RNA-TARGETED THERAPEUTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL RNA-TARGETED THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HOSPITAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HOSPITAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HOSPITAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 153. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 154. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 155. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 156. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 157. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. NATO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 163. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 164. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 165. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 167. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. G7 HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 190. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 191. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 193. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 194. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 195. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 197. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. GCC HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 231. GERMANY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 232. GERMANY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. GERMANY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 234. GERMANY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 235. GERMANY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 236. GERMANY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 237. GERMANY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 238. GERMANY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. GERMANY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. GERMANY HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 241. CANADA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. CANADA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. CANADA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 244. CANADA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 245. CANADA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 246. CANADA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 247. CANADA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 248. CANADA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. CANADA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. CANADA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 251. JAPAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 252. JAPAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. JAPAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 254. JAPAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 255. JAPAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 256. JAPAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 257. JAPAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 258. JAPAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. JAPAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. JAPAN HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED KINGDOM HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED KINGDOM HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED KINGDOM HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED KINGDOM HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED KINGDOM HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED KINGDOM HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED KINGDOM HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED KINGDOM HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED KINGDOM HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED KINGDOM HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 271. BRAZIL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. BRAZIL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. BRAZIL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 274. BRAZIL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 275. BRAZIL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 276. BRAZIL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 277. BRAZIL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 278. BRAZIL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. BRAZIL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 280. BRAZIL HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 281. MEXICO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 282. MEXICO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. MEXICO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 284. MEXICO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 285. MEXICO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 286. MEXICO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 287. MEXICO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 288. MEXICO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. MEXICO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 290. MEXICO HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 291. FRANCE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 292. FRANCE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. FRANCE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 294. FRANCE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 295. FRANCE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 296. FRANCE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 297. FRANCE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 298. FRANCE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. FRANCE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 300. FRANCE HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 301. INDIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 302. INDIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. INDIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 304. INDIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 305. INDIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 306. INDIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 307. INDIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY MOLECULE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 308. INDIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. INDIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 310. INDIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 311. AUSTRALIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 312. AUSTRALIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. AUSTRALIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ON DEMAND, 2018-2032 (USD MILLION)
  • TABLE 314. AUSTRALIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 315. AUSTRALIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY C1-ESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 316. AUSTRALIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 317. AUSTRALIA HEREDITARY ANGIOEDEMA THERAPEUTICS MARKET SIZE